UK-based provider of a microfluidics-driven drug discovery platform using biophysical sciences and artificial intelligence tools to map and modulate biomolecular condensates
Transition Bio has raised €47M across 1 funding round from 5 investors, most recently a Series A round in Jun 2022. Based in Cambridge, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-06-03 | Series A | €47M |
| Bristol Myers Squibb,Lifeforce Capital,Magnetic Ventures,Northpond Ventures,Taiho Ventures |
| View deal → |
